FDA Inspection 1259789 — Glaxo Wellcome S.A.
The FDA completed an inspection of Glaxo Wellcome S.A. on Jun 8, 2022 in Aranda De Duero. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Jun 8, 2022
- Fiscal Year
- 2022
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Aranda De Duero (Spain)
Additional Details
Mutual Recognition Agreement (MRA)